|
Indication for ACE/ARB
|
ACE/ARB
|
No AKI
|
AKI
|
|---|
| | |
N (%)
|
N (%)
|
|
No
|
No
|
83,724 (97.8%)
|
1,846 (2.2%)
|
| |
Yes
|
18,331 (96.2%)
|
721 (3.8%)
|
|
Yes
|
No
|
25,542 (94.1%)
|
1,594 (5.9%)
|
| |
Yes
|
72,044 (94.2%)
|
4,473 (5.8%)
|
|
No AKI/AKIN1 versus AKIN2/AKIN3
|
|
Indication for ACE/ARB
|
ACE/ARB
|
No AKI/AKIN1
|
AKIN2/AKIN3
|
| | |
N (%)
|
N (%)
|
|
No
|
No
|
85,428 (99.83%)
|
142 (0.17%)
|
| |
Yes
|
18,989 (99.67%)
|
63 (0.33%)
|
|
Yes
|
No
|
27,032 (99.62%)
|
104 (0.38%)
|
| |
Yes
|
76,267 (99.67%)
|
250 (0.33%)
|
- AKI (acute kidney injury), AKIN1 (acute kidney injury network stage 1), AKIN2 (acute kidney injury network stage 2), AKIN3 (acute kidney injury network stage 3), CKD (chronic kidney disease), ACE (angiotensin converting enzyme inhibitor), ARB (angiotensin receptor blocker), IHD (ischaemic heart disease), BP (blood pressure).
